Biosimilars | Specialty

The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.


Biosimilars Enter US Market, Poised to Impact Cancer Treatment

February 5th 2020

Adam M. Brufsky, MD, PhD, FACP, discusses the emergence of biosimilars in oncology and how he anticipates they will change the paradigm.

Rituximab Biosimilar Nears EU Approval for Oncologic and Other Indications

February 4th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for the rituximab biosimilar PF-05280586 for the treatment of patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.

Three Biosimilars Entering US Oncology Market at Substantial Discounts

January 24th 2020

Three biosimilars—bevacizumab-bvzr (Zirabev), rituximab-pvvr (Ruxience), and trastuzumab-qyyp)—will become available in the United States at a substantial discount to their reference products.

Experts Highlight Benefits and Challenges With Biosimilars in Breast Cancer

January 22nd 2020

Ruth O’Regan, MD, and Adam M. Brufsky, MD, PhD, FACP, both discuss the emergence of trastuzumab biosimilars in breast cancer.

Biosimilars Expected to Become More Widespread in US Oncology Market

January 22nd 2020

Francisco J. Esteva, MD, PhD, discusses the cost-saving potential of biosimilars in breast cancer and historical experience with their use.

Dr. Burris on the Incorporation of Biosimilars in Oncology

January 10th 2020

Howard "Skip" A. Burris, III, MD, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the incorporation of biosimilars in oncology.

Similarity of Biosimilars and Biologics

January 4th 2020

Thomas Helleday, PhD, professor of Translational Oncology, director of the Weston Park Cancer Centre, Department of Oncology and Metabolism, The Medical School, The University of Sheffield, discusses the similarity of biosimilars and biologics.

Biosimilars Poised to Drive Down Treatment Costs in Oncology

December 23rd 2019

Julie R. Gralow, MD, discusses the emergence of biosimilars in the United States and globally.

FDA Approval Sought for Rituximab Biosimilar

December 20th 2019

A biologics license application has been submitted to the FDA for the rituximab biosimilar ABP 798.

Dr. Gralow on the Global Impact of Biosimilars

December 20th 2019

Julie R. Gralow, MD, clinical director, Breast Medical Oncology, Seattle Cancer Care Alliance, professor, medical oncology, University of Washington School of Medicine, discusses the global impact of biosimilars in HER2-positive breast cancer.

Dr. O'Regan on Biosimilar Education in Breast Cancer

December 19th 2019

Ruth O’Regan, MD, discusses patient education as biosimilars are implemented into practice for breast cancer.

Dr. Brufsky on Trastuzumab Biosimilars in Breast Cancer

December 19th 2019

Adam M. Brufsky, MD, PhD, discusses the utility of trastuzumab biosimilars in breast cancer.

Dr. Klebanoff on Biosimilars Reducing Financial Toxicity in Breast Cancer

December 19th 2019

Christopher A. Klebanoff, MD, discusses using biosimilars to reduce financial toxicity in breast cancer.

Dr. Kruse on How to Converse About Biosimilars in Breast Cancer

December 18th 2019

Megan Kruse, MD, discusses how to converse with patients with breast cancer about implementing biosimilars in treatment.

Dr. Gralow on the Science of Biosimilars and Implementation in Breast Cancer

December 18th 2019

Julie R. Gralow, MD, discusses the science of biosimilars and their implementation in breast cancer.

Dr. Cristofanilli on the Need for Biosimilars in Oncology

December 16th 2019

Massimo Cristofanilli, MD, discusses the need for biosimilars in oncology.

Dr. Pagel on Biosimilars and Cost Consciousness in Oncology

December 13th 2019

John M. Pagel, MD, PhD, discusses the use of biosimilars in oncology and the importance of cost consciousness.

Dr. Hays on Potential for PARP Inhibitor Combinations in Ovarian Cancer

December 11th 2019

John Hays, MD, PhD, discusses the potential for PARP inhibitor combinations in patients with ovarian cancer.

Dr. Eradat on Rituximab Biosimilar in CD20+ B-Cell Non-Hodgkin Lymphoma and CLL

December 10th 2019

Herbert A. Eradat, MD, discusses the implications of the FDA approval of rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) in patients with CD20-positive B-cell Non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. McBride on the Potential of Biosimilars in Oncology

December 5th 2019

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses the potential utility of biosimilars in oncology.